JAK2 Inhibitor TQ05105 clinical trials
Also written TQ05105.
How each study uses JAK2 Inhibitor TQ05105 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the JAK2 Inhibitor TQ05105 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2026 (4)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 0
Often tested with
Tested in the same studies.
Rabeprazole (1) · BET Inhibitor TQB3617 (1)
Related medicines
As reviewed, each with the page that says it.
- One of JAK inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test JAK2 Inhibitor TQ05105.
- Dec 2026QT Interval/Corrected QT Interval (QT/QTc) Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy ParticipantsPhase 1 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Dec 2026Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 TabletsPhase 1 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Dec 2026A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)Phase 1/2 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Nov 2027A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host DiseasePhase 2 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Studies
Open first, then newest update. How each study uses JAK2 Inhibitor TQ05105 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host DiseaseRecruitingPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06300320Written as TQ05105 tablets
- A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk MyelofibrosisRecruitingPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07551427Written as TQ05105 Tablets (Rovadicitinib Tablets)
- To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment SubjectsRecruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07480824Written as TQ05105
- A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)RecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06122831Written as TQ05105 Tablets
- QT Interval/Corrected QT Interval (QT/QTc) Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy ParticipantsActive, not recruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07708272Written as TQ05105 tablets
- Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 TabletsActive, not recruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07608666Written as TQ05105 tablets
- A Study of TQ05105 Tablets in Subjects With Myeloproliferative NeoplasmsCompletedPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04339400Written as TQ05105
- A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)TerminatedPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04941404Written as TQ05105 tablets
- A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk MyelofibrosisCompletedPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05020652Written as TQ05105 tablets
- A Clinical Trial of Mass Balance of [14C] TQ05105 in Healthy Chinese SubjectsCompletedPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07293390Written as TQ05105
- A Study to Evaluate Drug-Drug Interaction of TQ05105 TabletsCompletedPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06024915Written as TQ05105 tablets
- A Study of TQ05105 in Patients With Chronic Graft Versus Host DiseaseActive, not recruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04944043Written as TQ05105 Tablet
- TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant PatientsTerminatedPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06388759Written as TQ05105 Tablets
- To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment SubjectsCompletedPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06598956Written as TQ05105
- To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult SubjectsCompletedPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05982106Written as TQ05105 Tablets
- A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis(HLH)Status unknownPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04326348Written as TQ05105